See the DrugPatentWatch profile for segluromet
Segluromet is a brand name for the medication containing the active ingredients ertugliflozin and sitagliptin [1]. It is used to treat type 2 diabetes [1]. Ertugliflozin belongs to a class of drugs called sodium-glucose cotransporter-2 (SGLT2) inhibitors, while sitagliptin is a dipeptidyl peptidase-4 (DPP-4) inhibitor [1].
How does Segluromet help manage type 2 diabetes?
Segluromet works by combining two different mechanisms to lower blood sugar levels [1]. Ertugliflozin inhibits SGLT2 in the kidneys, which reduces the reabsorption of glucose and increases its excretion in the urine [1]. Sitagliptin works by increasing levels of incretin hormones, which in turn stimulate insulin release and decrease glucagon secretion from the pancreas [1]. This dual action helps to improve glycemic control in individuals with type 2 diabetes [1].
When might a doctor prescribe Segluromet?
Doctors may prescribe Segluromet as an adjunct to diet and exercise for adults with type 2 diabetes who are not adequately controlled on monotherapy with either ertugliflozin or sitagliptin, or when dual therapy with both agents is appropriate [1]. It can also be prescribed for patients whose diabetes is inadequately controlled on their current regimen [1].
What are the active ingredients in Segluromet?
The active ingredients in Segluromet are ertugliflozin and sitagliptin [1]. Ertugliflozin is dosed at 7.5 mg or 15 mg, and sitagliptin is dosed at 100 mg [1].
When does Segluromet's patent protection expire?
Information regarding specific patent expiry dates for Segluromet, or its active ingredients ertugliflozin and sitagliptin, would be available through drug patent databases [2]. These databases track patents, exclusivity periods, and potential for generic competition for pharmaceutical products [2]. For detailed patent information on ertugliflozin and sitagliptin, DrugPatentWatch.com can be a valuable resource [2].
Are there other medications that combine SGLT2 inhibitors and DPP-4 inhibitors?
While Segluromet is one such combination, other medications may also combine different classes of antidiabetic drugs [3]. The development of fixed-dose combinations aims to simplify treatment regimens and improve patient adherence [3].
What are the potential side effects of Segluromet?
As Segluromet contains both ertugliflozin and sitagliptin, patients may experience side effects associated with either of these drug classes. Common side effects of SGLT2 inhibitors can include urinary tract infections and genital yeast infections [1]. DPP-4 inhibitors like sitagliptin can sometimes cause nasopharyngitis and upper respiratory tract infections [1]. Specific warnings and precautions are detailed in the drug's prescribing information [1].
How is Segluromet administered?
Segluromet is taken orally once a day [1]. It can be taken with or without food [1].
What clinical studies support the use of Segluromet?
Clinical trials have evaluated the efficacy and safety of Segluromet, demonstrating its ability to lower HbA1c levels in patients with type 2 diabetes when used as an add-on therapy [1]. These studies form the basis for its approval and prescribing recommendations.
Sources:
1. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/209441s000lbl.pdf
2. https://drugpatentwatch.com/
3. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5486719/